. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Bioorg Med Chem. 2013 Aug 13;21(21):10.1016/j.bmc.2013.08.006. doi: 10.1016/j.bmc.2013.08.006

Table 5.

In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the GVR35 CNS mouse model.^a

Code^b	Dosage (po, mg/kg)/no. of days administered	No. of mice cured ^c	MSD^d
2c^e(2a)	100/5	3/5	>167.8
3c^e(3a)	100/5	5/5	>180
4c^e(4a)	100/5	5/5	>180

11(10)	100/5	0/5	69
12(10)	100/5	2/5	>173.8
	100/10	3/4	>180.0
24b(23b)	100/5	0/5	67.2
25a(23a)	100/5	0/5	95.2

See Ref. 5 for details of GVR35 CNS mouse model.

Code for parent of prodrug in parenthesis.

Cure defined as survival for more than 180 days after infection without showing a parasitemia relapse.

MSD (mean survival days) was determined for mice with and without parasitemia relapse.

Data from Ref. 5